1 / 6

Jakavi 15mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

Jakavi 15mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production .

RobbieRoyce
Télécharger la présentation

Jakavi 15mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. APPLE PHARMACEUTICALS Is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines. 

  2. RUXOLITINIB JAKAVI 15MG

  3. DESCRIPTION INDICATIONS Jakavi 15mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production. Jakavi 15mg is prescription drug provided under supervision of doctors or pharmacists • Jakavi 10mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.

  4. MECHANISM • Ruxolitinib is also knowns kinase inhibitor which is discriminating for the Janus analogue Kinases (JAK) 1 and 2. These kinases are required for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. • The communicate process involves signal transducers and transcription activators (STAT) that modulate gene expression. Patients having myelofibrosis consist of abnormal JAK1 and JAK2 activity,ThereforeRuxolitinibfunction to regulate this.

  5. DRUG INTERACTION • STORAGE Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction. Interaction of Jakavi 15mg with strong CYP3A4 inhibitors will increases Ruxolitinib exposure. Interaction of Jakavi 15mg with strong CYP3A4 inducers will decreases Ruxolitinib exposure. • Jakavi 15mg stored at 20° to 25° • Protect away from light and moisture • Dispense in its original container

  6. CONTACT US ADDRESS • Apartment No.304 A Wing, Shiva Shakthichs ltd, JP Road, Near ApnaBazar,Andheri(West),Mumbai - 400058.Maharashtra. CALL +91-9987711567 EMAIL applepharamaceutical@gmail.com

More Related